Trials Sponsors Conditions Drugs Pricing

Conditions

Retroperitoneal Liposarcoma

Keywords

Sarcomaliposarcomaretroperitoneal

Outcome Measures

Primary Outcomes (1)

Abdominopelvic recurrence-free survival (ARFS). .
Defined as the time from the date of treatment start (either surgery, chemo or RT) for 1st recurrent LPS to the date of radiological abdominopelvic relapse or death whichever occurred first. Liver metastases will be regarded as distant metastatic events. rather than abdominopelvic relapse
Up to 5 years.

Secondary Outcomes (14)

Overall survival
Up to 5 years.
Cumulative incidence of 2nd local recurrence (in a competing risk framework)
Up to 5 years.
Cumulative incidence of distant metastases (in a competing risk framework).
Up to 5 years.
Cumulative incidence of in-field relapse for those who had preoperative radiotherapy (in a competing risk framework)
Up to 5 years.
Pathological response using the EORTC-STBSG criteria.
At surgical resection.
+9 more secondary outcomes

Study Arms (2)

Surgery with preoperative radiotherapy

This includes patient who have had any chemotherapy.

Surgery without preoperative radiotherapy

This includes patients who had surgery alone, surgery with postoperative radiotherapy and/or any chemotherapy.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Patients diagnosed with localized, resectable recurrent retroperitoneal liposarcoma attending and having treatment at the study site.

You may qualify if:

Adult age ≥ 18 presenting with first recurrent well-differentiated and/or dedifferentiated liposarcoma of retroperitoneal space or pelvis after previous macroscopically complete resection (R0/R1 resection)

Sponsors & Collaborators

Australia and New Zealand Sarcoma Association
Otherlead

Study Sites (13)

Emory Winship Cancer Institute

Atlanta, Georgia, 30322, United States

RECRUITING

Jennifer GlassCONTACT404-778-1900 jennifer.glass@emoryhealthcare.org

Kenneth CardonaPRINCIPAL INVESTIGATOR

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

NOT_YET_RECRUITING

Kodey SilknitterCONTACT

MeSH Terms

Conditions

Retroperitoneal liposarcomaSarcomaLiposarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsNeoplasms, Adipose Tissue

Study Officials

Angela Hong
Chris O'Brien Lifehouse
PRINCIPAL INVESTIGATOR

Central Study Contacts

Janina Chapman

CONTACT

61414316490 janina.chapman@petermac.org

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

January 4, 2026

First Posted

January 30, 2026

Study Start

September 5, 2024

Actual (reported)

Primary Completion

December 2032

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (14)

Study Arms (2)

Surgery with preoperative radiotherapy

Surgery without preoperative radiotherapy

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (13)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (14)

Study Arms (2)

Surgery with preoperative radiotherapy

Surgery without preoperative radiotherapy

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (13)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations